Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19 Antigen Template: FDA Adds Info On Asymptomatics Studies, Multiplex Tests

Executive Summary

The US agency on 26 October updated its emergency use authorization template to include a somewhat lengthy section on recommendations for clinical studies of asymptomatic people, as well as guidance for makers of multiplex tests that screen for the coronavirus and influenza.

You may also be interested in...



87636 And 87637: New CPT Codes From AMA For COVID-19/Flu Combo Antigen Tests

The American Medical Association has added two new Current Procedural Terminology (CPT) codes for reporting antigen tests that detect COVID-19 and influenza. And a third new code, 87811, should be used to report “infectious agent antigen detection by immunoassay with direct visual observation.”

FDA Boosts Development Of OTC COVID-19 Tests With New Template

A new template from the US FDA explains what information the agency wants to see in regulating COVID-19 tests to be performed outside the laboratory environment.

Speaking Of Medtech, Ep. 10: FDA’s TAP Pilot

In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT142959

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel